AI Article Synopsis
- The study aimed to measure prostate volume changes using transrectal ultrasound (TRUS) after permanent prostate brachytherapy (PPB) and compare these with computed tomography (CT) measurements for potential real-time dosimetry applications.
- Between July 2000 and January 2003, 177 patients underwent PPB, with 136 completing imaging studies, showing mean prostate volume measurements before and after the procedure.
- Results indicated variability in volume measurements post-implant, particularly in larger prostates, highlighting the importance of accurate imaging for effective treatment planning in PPB.
Article Abstract
Purpose: To quantify prostate volume (pvol) changes with transrectal ultrasound (TRUS) immediately after permanent prostate brachytherapy (PPB) and to correlate these changes with postimplant computed tomography (CT) volumetrics. To provide data relevant to evaluating the potential of TRUS-based image fusion for intraoperative dosimetry.
Methods And Materials: Between July 2000 and January 2003, 177 patients underwent (125)I PPB monotherapy at our institution, and 165 patients provided research authorization. A total of 136 patients (82%) completed 4 imaging studies: planning TRUS, intraoperative pre- and postimplant TRUS, and CT.
Results: Mean planning TRUS pvol was 38.7 +/- 11.7 cc standard deviation (SD), 95% confidence interval (CI) (36.7, 40.7). Mean intraoperative TRUS pvol preimplant was 37.1 +/- 11.7 cc SD, 95% CI (35.1, 39.0), and postimplant was 44.5 +/- 15.1 cc SD, 95% CI (42.0, 47.1). The mean ratio of postimplant:preimplant intraoperative TRUS pvols was 1.2 +/- 0.2 SD, 95% CI (1.18, 1.24), and the difference in mean values was 7.5 cc (p < 0.0001). CT performed within 1 day revealed a mean pvol of 47.9 +/- 15.7 cc SD, 95% CI (45.2, 50.5). The mean volumetric ratio of CT to postimplant TRUS pvol was 1.13 +/- 0.36, 95% CI (1.07-1.19).
Conclusions: Whereas mean preimplant step-section TRUS pvol measurements are similar, postimplant TRUS and CT measurements have greater variability that depend on initial pvol. CT-based pvol measurements determined a mean of 10.6 hours after implant were more likely to be identical to those of immediate postimplant TRUS in prostates >33 cc. These data are relevant for establishing accuracy in image-fusion based approaches being investigated for real-time intraoperative PPB dosimetry.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijrobp.2004.04.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Feasibility of balloon rectal spacer implantation in HDR and LDR brachytherapy for prostate cancer treatment.
Brachytherapy
November 2024
Radiotherapy Institute, Oncology Division, Rambam Health Care Campus, Haifa, Israel.
Article Synopsis
- This study assesses a biodegradable balloon rectal spacer for two prostate cancer patients receiving low dose (LDR) and salvage high dose (HDR) radiation therapy to protect the rectum from radiation exposure.
- The spacer was successfully implanted using ultrasound guidance, creating a 14-15mm gap between the prostate and rectum, with dosimetry metrics indicating effective radiation delivery to the prostate while minimizing rectal dose.
- Both patients tolerated the procedure well, experiencing no complications during a 6-month follow-up, suggesting the spacer is a safe and effective tool in radiation therapy for prostate cancer.
Comparison between postoperative TRUS-CT fusion with MRI-CT fusion for postimplant quality assurance in prostate LDR permanent seed brachytherapy.
Brachytherapy
October 2021
British Columbia Cancer Center for the Southern Interior, Dept of Radiation Oncology. Dept of Radiation Physics, British Columbia, Canada.
PURPOSE/OBJECTIVE Permanent seed Low-Dose-Rate brachytherapy is planned and delivered using transrectal ultrasound (TRUS). Post-implant evaluation for quality assurance is usually performed using Computed Tomography (CT). Registration of the CT images with MRI reduces subjectivity in contouring by improving prostate edge detection.
View Article and Find Full Text PDFLive implant dosimetry may be an effective replacement for postimplant computed tomography in localized prostate cancer patients receiving low dose rate brachytherapy.
Brachytherapy
October 2021
School of Medicine, National University of Ireland, Galway, Ireland; Department of Radiation Oncology, Galway Clinic, Ireland; Prostate Cancer Institute, National University of Ireland, Galway, Ireland. Electronic address:
Purpose: To determine if Live Implant Dosimetry (LIDO) utilizing intraoperative transrectal ultrasound (TRUS) is equivalent to postimplant CT dosimetry (either day 0 or day 30) in patients with localized prostate cancer (PC) treated with low dose rate (LDR) prostate seed brachytherapy.
Methods And Materials: The treated population consisted of 628 men with localized (T1-T2) PC. All d'Amico risk categories (low, intermediate, and high) were included, and 437 patients were treated with monotherapy (160 Gy) [low and low tier intermediate], and the remainder (191) [high tier intermediate and high risk] with an implant boost (106 Gy) post external beam radiation, to a volume including the prostate and seminal vesicles (46 Gy).
Evaluation of transrectal ultrasound-based dosimetry for brachytherapy of prostate cancer: a single-center experience.
J Contemp Brachytherapy
August 2020
Department of Urology, Xiangya Hospital, Central South University, Changsha, City, Hunan Province, P. R. China.
Purpose: To explore the possibility of intraoperative transrectal ultrasound (TRUS)-based dose verification in transperineal brachytherapy (BT) with iodine-125 (I) seeds for prostate cancer.
Material And Methods: Fifteen patients with prostate cancer were treated using BT with I seeds. Post-implant TRUS and computed tomography (CT) images were imported into treatment planning system (TPS) for dosimetry.
Prostate brachytherapy intraoperative dosimetry using a combination of radiographic seed localization with a C-arm and deformed ultrasound prostate contours.
Brachytherapy
May 2021
Department of Medical Physics, Vancouver Center, BC Cancer, Vancouver, British Columbia, Canada.
Purpose: The purpose of the study was to assess the feasibility of performing intraoperative dosimetry for permanent prostate brachytherapy by combining transrectal ultrasound (TRUS) and fluoroscopy/cone beam CT [CBCT] images and accounting for the effect of prostate deformation.
Methods And Materials: 13 patients underwent TRUS and multiview two-dimensional fluoroscopic imaging partway through the implant, as well as repeat fluoroscopic imaging with the TRUS probe inserted and retracted, and finally three-dimensional CBCT imaging at the end of the implant. The locations of all the implanted seeds were obtained from the fluoroscopy/CBCT images and were registered to prostate contours delineated on the TRUS images based on a common subset of seeds identified on both image sets.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!